Biohaven and Merus will co-develop three bispecific ADC programs by combining Merus' Biclonics® platform with Biohaven's advanced linker, payload, and conjugation technologies.

Biohaven's Linker-Payload Platform:
1. Site-specific conjugation ensures consistent DARs for optimal efficacy.

2. Stable amide bonds minimize payload leakage and off-target toxicity.

3. Native antibodies streamline manufacturing without chemical modifications.

4. The proprietary Topo1 inhibitor payload enhances bystander effects and immunogenic cell death.